Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission - Wikidata - awgldk - TriplyDB

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

http://www.wikidata.org/entity/Q36212437

about

Immunotherapy of Childhood Sarcomas Enhancing Cancer Immunotherapy Via Activation of Innate Immunity Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors Radioimmunotherapy of human tumours Overview and recent advances in the treatment of neuroblastoma.Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy Pediatric Rhabdomyosarcoma.Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies.GD2-targeted immunotherapy and radioimmunotherapy Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8 Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Immunotherapy in pediatric malignancies: current status and future perspectives Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma.Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma Osteochondroma in long-term survivors of high-risk neuroblastoma.Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells.HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.Advances in chimeric antigen receptor immunotherapy for neuroblastoma.Immune-based therapies for childhood cancer.New immunotherapeutic strategies for the treatment of neuroblastoma.Targeted approaches to childhood cancer: progress in drug discovery and development.

P2860

Q26795369-8E4EAED7-0837-4138-8889-AC95186D57A3 Q26796313-A3D85DA0-E6A3-4753-B8CB-73C42DF3EF6B Q26825652-94A44AAF-B2B5-4E56-9E62-7174ED4C6414 Q27678257-8FED75D4-B7C8-4E26-A3B7-AEB14C0E80EB Q28088825-80C89E0C-D724-4709-8F34-7A589C69306C Q30238693-15024CF1-1F52-4A96-A270-40EA74799EC3 Q33408675-3BAAF11C-0ABE-4DE6-B546-84ABF993626A Q33438641-BCA9EB19-ECDC-4434-85E1-1155BEEE746D Q33659849-1DCFECE1-B6AD-489E-A907-6A533785296B Q33785744-B3655BE9-DD62-439F-BFE4-0818737B5E1A Q33842070-B8FE43B7-0B45-4F47-80EA-EED0810015F0 Q34389202-D960F085-C8E4-4B09-91CF-4EFE9D7124CB Q34484061-43761A82-958B-4A66-8940-F3A3B56FEDFC Q34625339-65705869-E310-4C6C-83E3-E82E326E4B65 Q34939364-97846EB9-1766-4836-8B8C-ADDEEADD4FA4 Q35077703-72FC503E-1CDF-4DDE-9D14-14BC1EF581B2 Q35077759-618C3482-B84D-4B1D-9B21-3E4EDB838EDE Q35102499-8BE35D16-0059-4B7A-A313-BCC8A659C69F Q35152029-AFF9A7FF-89EA-4BED-9623-81945256AF91 Q35283020-80C3B52E-F078-4202-A817-671365D8FFF8 Q35654544-90FF5E4A-3720-4711-BFEC-C2A628A5F99E Q35798960-4ECB3A02-754A-46D1-AF47-A2CAD5B095E0 Q35860917-6FBD0794-01D4-495D-95C0-10E91739A3FF Q36597374-32BE4F47-7303-4822-A1F3-8D2B1ADF8D40 Q36691818-04408615-285E-4134-A058-B9ABDA77FDE2 Q36772203-8499858B-7806-4C51-9B6F-00566413FE93 Q36782374-DD7404B9-4A76-484E-9777-FF2AA7B2EADE Q36908714-E6EB954D-1F4A-4637-B0E0-20899FA3379C Q37078941-CB31B166-811C-4C89-B641-CEC319C6F9BA Q37130228-FBD6786F-64F1-49B2-BB5E-8451C27682A9 Q37145905-6DEE08E3-DD72-4F7C-97C7-DA2644E160FC Q37265479-142C8357-EB89-4A59-BD8D-DB1BC59981EB Q37624276-9E68D0EC-6BEF-48EB-B478-8C86BCD4FF6C Q37654781-108FB53E-5B59-4D73-8CBC-7449A20697B6 Q37680008-DF88E8A5-FAF0-46C3-A765-68FE340E337F Q38079519-3C31FC6D-3576-487F-B348-B7BE14E30AA2 Q38170885-BF3D2288-DF7D-47B6-860C-99E298C371FD Q38263108-987CC507-5407-44D8-B48E-20B82BEB24D9 Q38389316-53F7B647-6A7A-4274-B110-FBBB69C8FB64 Q38404462-7F97BD24-8C25-4868-ACD9-10D84C80865C

P2860

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

http://www.wikidata.org/entity/Q36212437

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Murine anti-GD2 monoclonal ant ...... uroblastoma in first remission

@ast

Murine anti-GD2 monoclonal ant ...... uroblastoma in first remission

@en

type

label

Murine anti-GD2 monoclonal ant ...... uroblastoma in first remission

@ast

Murine anti-GD2 monoclonal ant ...... uroblastoma in first remission

@en

prefLabel

Murine anti-GD2 monoclonal ant ...... uroblastoma in first remission

@ast

Murine anti-GD2 monoclonal ant ...... uroblastoma in first remission

@en

P1433

Q36212437-0DE29907-89FE-4166-90C6-D68E14FA0F03

P1476

Q36212437-21F8FEF9-80BB-45FD-AE51-A3EEEE619837

P2093

Q36212437-1C9D1F87-4B81-4D7C-AC45-BAA6B5DB3BE0

Q36212437-1CEF02CE-490E-4E48-9BA0-F5D3E57D2673

Q36212437-292F23E1-FBDA-4471-8D6E-493C811F3769

Q36212437-A34020CF-5CBC-4475-96B9-C97E94CE479B

Q36212437-A774661A-E41F-436A-92BF-D4C3CCD9A5B4

Q36212437-D3008D27-6DD6-44A4-A200-AC49E7539418

P2860

Q36212437-0802336D-EBF2-4C9A-9157-659343606F53

Q36212437-0CF81C24-1C33-4618-A1BE-799F46D9909C

Q36212437-294C30E7-C821-4849-B175-64759DE4DD72

Q36212437-33D38397-18F2-4BBF-9DC2-B6792F896E8C

Q36212437-36080A04-7CD8-4992-B5AE-6A06B83E63B1

Q36212437-389EDFEE-9030-467D-9780-61269CAEA9CB

Q36212437-3EE01A15-41F8-403A-80E0-FB1B61295C08

Q36212437-3F54B3F5-0E0D-43FD-844E-8D24D024A31D

Q36212437-4133111D-8010-4185-AD81-D7A3BF947A7F

Q36212437-41FA3547-8BCE-418E-9BF0-812E75FDABF7

P304

Q36212437-3C8D18E8-A6BE-4652-ADD3-80D5E487FA92

P31

Q36212437-11D86077-E8A9-458B-93DD-B21F3570F0BE

P356

Q36212437-F0C58242-A85C-4531-AFDE-C7A35303886A

P407

Q36212437-638284E2-B115-436B-8438-345418FADCDC

P433

Q36212437-80E7F250-ED37-4FE0-A6BA-FFD7F7791294

P478

Q36212437-3694D699-4028-421B-BA81-07BF773E0F8B

P50

Q36212437-2C5EFFFB-4A2A-444D-8170-9BDC9B4D7DA0

P577

Q36212437-B64626DE-7989-42FB-9CF2-60793AB9E5F7

P698

Q36212437-31A457E2-5298-40AA-8BFC-FF03E5C06EE2

P921

Q36212437-03230123-ADB1-4CFC-987B-E68797AE3FA6

Q36212437-339C74ED-B600-4D7F-8EB3-A5A8078B4E3A

P932

Q36212437-F8C76D29-A414-4137-ACDD-8005AE632209

P356

JCO.2011.41.3807

P1433

Journal of Clinical Oncology

P1476

Murine anti-GD2 monoclonal ant ...... uroblastoma in first remission

@en

P2093

Brian H Kushner

http://www.w3.org/2001/XMLSchema#string

Elizabeth Chamberlain

http://www.w3.org/2001/XMLSchema#string

Irene Y Cheung

http://www.w3.org/2001/XMLSchema#string

Irina Ostrovnaya

http://www.w3.org/2001/XMLSchema#string

Kim Kramer

http://www.w3.org/2001/XMLSchema#string

Nai-Kong V Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Cancer immunotherapy

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma.

Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets.

Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review.

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.

P304

3264-3270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.41.3807

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22869886

http://www.w3.org/2001/XMLSchema#string

P921

P932

3434986

http://www.w3.org/2001/XMLSchema#string